William Y.C. Chang
A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis
Chang, William Y.C.; Cane, Jennifer L.; Kumaran, Maruti; Lewis, Sarah; Tattersfield, Anne E.; Johnson, Simon R.
Jennifer L. Cane
Professor SARAH LEWIS firstname.lastname@example.org
Professor of Medical Statistics
Anne E. Tattersfield
SIMON JOHNSON email@example.com
Professor of Respiratory Medicine
Lymphangioleiomyomatosis (LAM) is characterised by lung cysts and airflow obstruction. Matrix metalloproteinases have been implicated in lung destruction in LAM. We performed a randomised, double-blind trial, comparing the matrix metalloproteinases inhibitor doxycycline with placebo on the progression of LAM.
23 females with LAM were randomised to doxycycline 100 mg daily for 3 months followed by 200 mg daily for 21 months, or matched placebo. Lung function, exercise capacity, quality of life and matrix metalloproteinases levels were measured.
21 patients completed 6 months of treatment, 17 completed 1 year of treatment and 15 completed 2 years of treatment. Eight withdrew from the trial due, four due to a pneumothorax and four because of other reasons. The mean±sd decline in FEV1, the primary endpoint, did not differ between the groups being -90±154 mL·year−1 in the placebo group and -123±246 mL·year−1 in the doxycycline group (difference -32.5, 95% CI -213–148; p=0.35). Doxycycline had no effect upon vital capacity, gas transfer, shuttle walk distance or quality of life. Urine matrix metalloproteinases-9 measurements were lower with doxycycline treatment (p=0.03).
Although with limited numbers we cannot completely exclude an effect of doxycycline, the lack of effect on any outcome makes it unlikely that doxycycline has a useful effect in LAM.
Chang, W. Y., Cane, J. L., Kumaran, M., Lewis, S., Tattersfield, A. E., & Johnson, S. R. (2014). A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. European Respiratory Journal, 43(4), doi:10.1183/09031936.00167413
|Journal Article Type||Article|
|Publication Date||Apr 1, 2014|
|Deposit Date||Feb 17, 2016|
|Publicly Available Date||Feb 17, 2016|
|Journal||European Respiratory Journal|
|Publisher||European Respiratory Society|
|Peer Reviewed||Peer Reviewed|
|Keywords||Rare Lung Diseases, Lung Proteases, Tuberous sclerosis|
|Copyright Statement||Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf|
|Additional Information||This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the copyright owner, the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication.|
Chang et al 2014 Eur Resp journal.pdf
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf
You might also like
Endocrine therapy for breast cancer: a model of hormonal manipulation